Filing Flows › Monte Rosa Therapeutics (GLUE) › Q3 2025
Monte Rosa Therapeutics (GLUE) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Monte Rosa Therapeutics (GLUE) reported revenue of $12.8M for the third quarter 2025 (Q3 2025), +39% from a year earlier and -45% from the quarter before. Operating margin was -258.3%, net loss $27.1M (212.1% of revenue).
Monte Rosa Therapeutics, Q3 2025: revenue $12.8M (+38% year over year), operating margin -258.3%, net loss $27.1M, operating cash flow $100M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $12.8M | -45% | +39% |
| Operating profit | −$33.0M | — | — |
| Net earnings | −$27.1M | — | — |
| Operating cash flow | $100M | — | — |
| Free cash flow | $99.8M | — | — |
What changed
Revenue was $12.8M in Q3 2025, up 39% year over year and down 45% from the previous quarter.
Operating costs exceeded revenue by $33.0M, an operating margin of -258.3%. Total costs grew 28% against revenue growth of 39%. The fastest-growing cost line was Research & development (+33%). The quarter ended with a net loss of $27.1M, wider than the previous quarter's $12.3M loss.
Operating cash flow was $100.4M. Non-cash charges added back $2.7M of depreciation and amortization and $4.4M of share-based compensation. Working capital and other items added $120.4M. Capital expenditures of $651K left free cash flow of $99.8M.
Questions
What was Monte Rosa Therapeutics' revenue in the third quarter 2025?
Monte Rosa Therapeutics (GLUE) reported revenue of $12.8M for the third quarter 2025 (Q3 2025), +39% from a year earlier and -45% from the quarter before.
Was Monte Rosa Therapeutics profitable in the third quarter 2025?
Operating loss was $33.0M (-258.3% of revenue) and net loss $27.1M.